Parexel talks global trial regulations at DIA 2011

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organisations, Pharmacology

US CRO Parexel says the pharmaceutical industry’s desire to access international markets is the key challenge facing regulatory experts in the contract research sector.

Alberto Grignolo, VP of global strategy and services told Outsourcing-pharma.com that “twenty years ago the name of the game was running clinical trials in the US and Europe…nowadays companies begin drug development with the world in mind.”

Dr Grignolo explained that this means developers must interact with a greater number of regulatory bodies worldwide, which in turn is driving demand for contract research organisations (CRO) that can assist in this process.

“This creates opportunities to be creative,” he continued “clients want to take medicines to the world and they are looking for partners, such as Parexel, that can help them do this.​”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars